Company Filing History:
Years Active: 2006-2010
Title: Innovations of Keril J Blight
Introduction
Keril J Blight is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of virology, particularly in relation to hepatitis C virus (HCV) research. With a total of 5 patents, his work has advanced the understanding and treatment of HCV.
Latest Patents
One of his latest patents focuses on cell lines permissive for HCV replication. This invention describes HCV variants that include polynucleotides comprising non-naturally occurring HCV sequences. These variants exhibit a transfection efficiency and ability to survive subpassage that surpasses that of wild-type polyprotein coding regions. The patent also details expression vectors that incorporate these polynucleotides and HCV variants, as well as methods for identifying cell lines that are permissive for HCV infection. Additionally, it discusses vaccines containing these polynucleotides in a pharmaceutically acceptable carrier and methods for inducing immunoprotection against HCV in primates. Another significant patent relates to highly permissive cell lines for HCV RNA replication, specifically the Huh-7.5 cell line, which has been designated with the A.T.C.C. number PTA-8561.
Career Highlights
Keril J Blight has dedicated his career to advancing the field of virology through innovative research and development. His work has not only contributed to scientific knowledge but has also paved the way for potential therapeutic applications in combating HCV.
Collaborations
Throughout his career, Keril has collaborated with esteemed colleagues, including Charles M Rice, III, and Charles Moen Rice, III. These collaborations have further enriched his research and contributed to the advancements in HCV studies.
Conclusion
Keril J Blight's contributions to the field of virology, particularly in HCV research, highlight his innovative spirit and dedication to scientific advancement. His patents and collaborative efforts continue to influence the landscape of hepatitis C research and treatment.